Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074449 | 0.98 | MAPT (0.49) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| SCHEMBL9453302 | 0.98 | MAPT (0.49) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| SCHEMBL7224713 | 0.98 | MAPT (0.49) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| SCHEMBL2207325 | 0.94 | L3MBTL1 (0.48) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| SCHEMBL15445274 | 0.89 | ALDH1A1 (0.47) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| SCHEMBL8342328 | 0.87 | TDP1 (0.44) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| SCHEMBL2203256 | 0.86 | L3MBTL1 (0.43) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| Malonic Acid SCHEMBL6827749 | 0.86 | TDP1 (0.44) | L3MBTL1MAPK1MAPTALDH1A1USP2 | |
| SCHEMBL11655565 | 0.84 | TDP1 (0.56) | L3MBTL1MAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL3113134 | 0.84 | MAPT (0.45) | L3MBTL1MAPK1MAPTALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| CN-110167934-B | Cyclobutane-and azetidine-containing monocyclic and spiro compounds as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3538526-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2006100606-A2 | PREPARATION OF BETA-AMINO ACID PRECURSORS VIA INDIUM (III) MEDIATED MARKOVNIKOV ADDITION AND KNOEVENAGEL CONDENSATION | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| WO-2004076425-A1 | IMPROVED SYNTHESIS OF MACROCYCLIC TETRAAMIDO COMPOUNDS AND NEW METAL INSERTION PROCESS | CARNEGIE MELLON UNIVERSITY (US) | 2004-09-10 | — | — | WO | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
| EP-0666262-B1 | Optically active compound, liquid crystal containing the same, liquid crystal device and display method using the same | CANON KK (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-5849217-A | Optically active compound, liquid crystal composition containing the same, liquid crystal device using the same, liquid crystal apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0666262-A1 | Optically active compound, liquid crystal containing the same, liquid crystal device and display method using the same | CANON KABUSHIKI KAISHA (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5141921-A | Natural, synthetic oils and 3-methyl-2-hexenoic acid and/or 7-octenoic acid; sedatives, stimulants | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1992-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | L3MBTL1 4413/4885MAPK1 1630/4885MAPT 1177/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | L3MBTL1 4419/4885MAPK1 1800/4885MAPT 1315/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | L3MBTL1 4326/4885MAPK1 1812/4885MAPT 864/4885 |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | L3MBTL1 4426/4885MAPK1 1740/4885MAPT 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.